Insulin Pumps Global Market - Forecast To 2028
Insulin Pumps Global Market - Forecast To 2028
Abstract
Insulin pumps are medical devices used for administering insulin in an automated, controlled, and precise manner. These devices are used in the treatment of diabetes mellitus know as continuous subcutaneous insulin infusion (CSII), these insulin systems help in avoiding medical errors which would lead to serious life-threatening circumstances or even sometimes to the death of a patient.
According to IQ4I analysis, the insulin pumps global market is expected to grow at a high single digit CAGR from 2021 to 2028 to reach $6,412.9 million by 2028. The insulin pumps market is segmented based on products, applications, pump utility, end-users and geography. The insulin pumps products market is segmented into insulin pumps and consumables, among them, insulin pumps held the largest share of the market in 2021 and are expected to grow at high single digit CAGR from 2021 to 2028. Insulin pumps are further sub-segmented into tethered insulin pumps and patch insulin pumps, among which the patch pump accounted for the largest share in 2021 and is expected to grow at high single digit CAGR from 2021 to 2028, the tethered pump market is expected to grow at strong CAGR from 2021 to 2028. The applications market is segmented into type 1 diabetes and type 2 diabetes, among them, the type 1 diabetes segment held the largest share in 2021 and is expected to grow at a high single digit CAGR from 2021 to 2028. The market based on pump utility is segmented into disposable pumps and durable pumps, among which durable pumps command the largest revenue in 2021, the disposable pump segment is expected to grow at high single digit CAGR from 2021 to 2028. The disposable pump market is further sub-segmented into fully disposable and partially disposable pumps, among which, the fully disposable segment commanded the largest revenue in 2021. The end-users market is classified into hospitals, ambulatory surgical centers, homecare and others. Among them, home healthcare commanded the largest share in 2021 and is expected to be the fastest-growing segment with high single digit CAGR from 2021 to 2028.
Geographically, North America is the largest market, with a share followed by Europe and the Asia Pacific. The APAC region is the fastest-growing region and is expected to grow at low teen CAGR from 2021 to 2028 presenting an array of growth opportunities and is likely to get the attention of new investors in the insulin pumps market. Growth in the Asian market is attributed to the rising prevalence of lifestyle diseases and government initiatives in establishing innovative technologies and demand for sophisticated medical services.
The insulin pumps market is expected to grow at high single digit CAGR from 2021 to 2028. An increase in the prevalence of diabetes, advantages of insulin pumps in the home care setting, and increasing distribution agreements, partnerships and collaboration activities, is the factors driving the market growth. The increasing product approvals and market expansion in emerging nations are expected to offer potential opportunities.
However, various factors like high cost, inadequate reimbursements, increasing product recalls and privacy concerns and safety issues associated with insulin pumps limit the growth of insulin pumps global market.
The insulin pumps global market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Major players in the insulin pumps market include Medtronic PLC (Ireland), Insulet Corporation (U.S.), Tandem Diabetes Care Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Ypsomed Holdings AG (Switzerland), Zealand Pharma (Valeritas) (Denmark), SOOIL development (South Korea), Debiotech S.A. (France), and Microtech Medical, Inc (China).
Content
1 EXECUTIVE SUMMARY 20
2 INTRODUCTION 25
2.1 KEY TAKEAWAYS 25
2.2 SCOPE OF THE REPORT 25
2.3 REPORT DESCRIPTION 26
2.4 MARKETS COVERED 28
2.5 STAKEHOLDERS 29
2.6 RESEARCH METHODOLOGY 29
2.6.1 MARKET SIZE ESTIMATION 31
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION 33
2.6.3 SECONDARY SOURCES 34
2.6.4 PRIMARY SOURCES 34
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES 35
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES 36
2.6.7 ASSUMPTIONS 36
3 MARKET ANALYSIS 40
3.1 INTRODUCTION 40
3.2 MARKET SEGMENTATION 41
3.3 FACTORS INFLUENCING MARKET 43
3.3.1 DRIVERS AND OPPORTUNITIES 44
3.3.1.1 The global rise in the prevalence and incidence of diabetes 44
3.3.1.2 Increase in the use of insulin pumps in-home care settings and disadvantages
of conventional methods over insulin pumps. 45
3.3.1.3 Increasing distribution agreements, partnerships and collaboration activities 46
3.3.1.4 Increase in product approvals 47
3.3.2 RESTRAINTS AND THREATS 47
3.3.2.1 High cost of the continuous subcutaneous insulin infusion therapy (CSII) 47
3.3.2.2 Inadequate reimbursement 48
3.3.2.3 Increased product recalls 49
3.3.2.4 Privacy concern and safety issues associated with insulin pumps 49
3.3.2.5 Stringent regulatory requirements for new products 50
3.4 REGULATORY AFFAIRS 52
3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION 52
3.4.1.1 ISO:9001: 2015 Quality Management System 52
3.4.1.2 ISO:13485 Medical Devices 52
3.4.2 U.S. 53
3.4.3 CANADA 55
3.4.4 EUROPE 56
3.4.5 INDIA 58
3.4.6 CHINA 59
3.4.7 JAPAN 60
3.5 FUNDING 61
3.6 DEALS 63
3.7 PORTER’S FIVE FORCE ANALYSIS 67
3.7.1 THREAT OF NEW ENTRANTS 68
3.7.2 THREAT OF SUBSTITUTES 69
3.7.3 RIVALRY AMONG EXISTING COMPETITORS 69
3.7.4 BARGAINING POWER OF SUPPLIERS 71
3.7.5 BARGAINING POWER OF BUYERS 71
3.8 CLINICAL TRIALS 72
3.9 SUPPLY CHAIN ANALYSIS 73
3.10 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 77
3.10.1 INSULIN PUMPS MARKET SHARE ANALYSIS 77
3.11 MARKET PENETRATION 80
3.11.1 GLOBAL TYPE 1 DIABETES INSULIN PUMP MARKET PENETRATION ANALYSIS 80
3.11.2 GLOBAL TYPE 2 DIABETES INSULIN PUMP MARKET PENETRATION ANALYSIS 82
3.11.3 N.A. TYPE 1 DIABETES INSULIN PUMP MARKET PENETRATION ANALYSIS 84
3.11.4 N.A. TYPE 2 DIABETES INSULIN PUMP MARKET PENETRATION ANALYSIS 85
3.11.5 E.U. TYPE 1 DIABETES INSULIN PUMP MARKET PENETRATION ANALYSIS 86
3.11.6 E.U. TYPE 2 DIABETES INSULIN PUMP MARKET PENETRATION ANALYSIS 87
3.11.7 APAC TYPE 1 DIABETES INSULIN PUMP MARKET PENETRATION ANALYSIS 88
3.11.8 APAC TYPE 2 DIABETES INSULIN PUMP MARKET PENETRATION ANALYSIS 89
3.11.9 ROW TYPE 1 DIABETES INSULIN PUMP MARKET PENETRATION ANALYSIS 90
3.11.10 ROW TYPE 2 DIABETES INSULIN PUMP MARKET PENETRATION ANALYSIS 91
4 INSULIN PUMPS GLOBAL MARKET, BY PRODUCTS 93
4.1 INTRODUCTION 93
4.2 INSULIN PUMP DEVICES 95
4.2.1 TETHERED INSULIN PUMP 100
4.2.2 PATCH INSULIN PUMP 103
4.3 CONSUMABLES 105
5 INSULIN PUMPS GLOBAL MARKET, BY APPLICATION 111
5.1 INTRODUCTION 111
5.2 TYPE 1 DIABETES 113
5.3 TYPE 2 DIABETES 116
6 INSULIN PUMPS GLOBAL MARKET, BY UTILITY 119
6.1 INTRODUCTION 119
6.2 DURABLE INSULIN PUMP 122
6.3 DISPOSABLE INSULIN PUMP 124
6.3.1 PARTIALLY DISPOSABLE INSULIN PUMP 128
6.3.2 FULLY DISPOSABLE INSULIN PUMP 129
7 INSULIN PUMPS GLOBAL MARKET, BY END-USER 131
7.1 INTRODUCTION 131
7.2 HOSPITALS 134
7.3 AMBULATORY SURGICAL CENTERS 136
7.4 HOME HEALTHCARE 137
7.5 OTHERS 140
8 INSULIN PUMPS GLOBAL MARKET, BY REGION 143
8.1 INTRODUCTION 143
8.2 NORTH AMERICA 146
8.2.1 U.S. 159
8.2.2 REST OF NORTH AMERICA 165
8.3 EUROPE 173
8.3.1 GERMANY 184
8.3.2 FRANCE 189
8.3.3 ITALY 194
8.3.4 REST OF EUROPE 199
8.4 APAC 205
8.4.1 JAPAN 217
8.4.2 CHINA 222
8.4.3 INDIA 227
8.4.4 REST OF APAC 232
8.5 REST OF THE WORLD 237
8.5.1 BRAZIL 250
8.5.2 TURKEY 255
8.5.3 OTHERS 260
9 COMPETITIVE LANDSCAPE 267
9.1 INTRODUCTION 267
9.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 268
9.3 NEW PRODUCT LAUNCH 271
9.4 APPROVAL 274
9.5 ACQUISITION 275
9.6 FUNDING 276
9.7 OTHERS 276
10 MAJOR COMPANIES 278
10.1 DEBIOTECH S.A. 278
10.1.1 OVERVIEW 278
10.1.2 FINANCIALS 279
10.1.3 PRODUCT PORTFOLIO 279
10.1.4 KEY DEVELOPMENTS 279
10.1.5 BUSINESS STRATEGY 279
10.1.6 SWOT ANALYSIS 280
10.2 INSULET CORPORATION 281
10.2.1 OVERVIEW 281
10.2.2 FINANCIALS 282
10.2.3 PRODUCT PORTFOLIO 284
10.2.4 KEY DEVELOPMENTS 285
10.2.5 BUSINESS STRATEGY 286
10.2.6 SWOT ANALYSIS 287
10.3 MEDTRONIC, PLC 288
10.3.1 OVERVIEW 288
10.3.2 FINANCIALS 289
10.3.3 PRODUCT PORTFOLIO 291
10.3.4 KEY DEVELOPMENTS 292
10.3.5 BUSINESS STRATEGY 293
10.3.6 SWOT ANALYSIS 294
10.4 MICROTECH MEDICAL, INC. 295
10.4.1 OVERVIEW 295
10.4.2 FINANCIALS 296
10.4.3 PRODUCT PORTFOLIO 296
10.4.4 KEY DEVELOPMENTS 296
10.4.5 BUSINESS STRATEGY 296
10.4.6 SWOT ANALYSIS 297
10.5 F. HOFFMANN-LA ROCHE AG. 298
10.5.1 OVERVIEW 298
10.5.2 FINANCIALS 299
10.5.3 PRODUCT PORTFOLIO 302
10.5.4 KEY DEVELOPMENTS 303
10.5.5 BUSINESS STRATEGY 304
10.5.6 SWOT ANALYSIS 305
10.6 SOOIL DEVELOPMENT CO. LTD. 306
10.6.1 OVERVIEW 306
10.6.2 FINANCIALS 306
10.6.3 PRODUCT PORTFOLIO 306
10.6.4 KEY DEVELOPMENTS 307
10.6.5 BUSINESS STRATEGY 307
10.6.6 SWOT ANALYSIS 308
10.7 TANDEM DIABETES CARE INC. 309
10.7.1 OVERVIEW 309
10.7.2 FINANCIALS 310
10.7.3 PRODUCT PORTFOLIO 312
10.7.4 KEY DEVELOPMENTS 312
10.7.5 BUSINESS STRATEGY 314
10.7.6 SWOT ANALYSIS 315
10.8 YPSOMED HOLDING AG. 316
10.8.1 OVERVIEW 316
10.8.2 FINANCIALS 317
10.8.3 PRODUCT PORTFOLIO 318
10.8.4 KEY DEVELOPMENTS 319
10.8.5 BUSINESS STRATEGY 320
10.8.6 SWOT ANALYSIS 321
10.9 ZEALAND PHARMA 322
10.9.1 OVERVIEW 322
10.9.2 FINANCIALS 323
10.9.3 PRODUCT PORTFOLIO 323
10.9.4 KEY DEVELOPMENTS 324
10.9.5 BUSINESS STRATEGY 324
10.9.6 SWOT ANALYSIS 325
10.10 ZHENGZHOU PHRAY TECHNOLOGY CO., LTD. 326
10.10.1 OVERVIEW 326
10.10.2 FINANCIALS 326
10.10.3 PRODUCT PORTFOLIO 326
10.10.4 KEY DEVELOPMENTS 326
10.10.5 BUSINESS STRATEGY 327
10.10.6 SWOT ANALYSIS 327
According to IQ4I analysis, the insulin pumps global market is expected to grow at a high single digit CAGR from 2021 to 2028 to reach $6,412.9 million by 2028. The insulin pumps market is segmented based on products, applications, pump utility, end-users and geography. The insulin pumps products market is segmented into insulin pumps and consumables, among them, insulin pumps held the largest share of the market in 2021 and are expected to grow at high single digit CAGR from 2021 to 2028. Insulin pumps are further sub-segmented into tethered insulin pumps and patch insulin pumps, among which the patch pump accounted for the largest share in 2021 and is expected to grow at high single digit CAGR from 2021 to 2028, the tethered pump market is expected to grow at strong CAGR from 2021 to 2028. The applications market is segmented into type 1 diabetes and type 2 diabetes, among them, the type 1 diabetes segment held the largest share in 2021 and is expected to grow at a high single digit CAGR from 2021 to 2028. The market based on pump utility is segmented into disposable pumps and durable pumps, among which durable pumps command the largest revenue in 2021, the disposable pump segment is expected to grow at high single digit CAGR from 2021 to 2028. The disposable pump market is further sub-segmented into fully disposable and partially disposable pumps, among which, the fully disposable segment commanded the largest revenue in 2021. The end-users market is classified into hospitals, ambulatory surgical centers, homecare and others. Among them, home healthcare commanded the largest share in 2021 and is expected to be the fastest-growing segment with high single digit CAGR from 2021 to 2028.
Geographically, North America is the largest market, with a share followed by Europe and the Asia Pacific. The APAC region is the fastest-growing region and is expected to grow at low teen CAGR from 2021 to 2028 presenting an array of growth opportunities and is likely to get the attention of new investors in the insulin pumps market. Growth in the Asian market is attributed to the rising prevalence of lifestyle diseases and government initiatives in establishing innovative technologies and demand for sophisticated medical services.
The insulin pumps market is expected to grow at high single digit CAGR from 2021 to 2028. An increase in the prevalence of diabetes, advantages of insulin pumps in the home care setting, and increasing distribution agreements, partnerships and collaboration activities, is the factors driving the market growth. The increasing product approvals and market expansion in emerging nations are expected to offer potential opportunities.
However, various factors like high cost, inadequate reimbursements, increasing product recalls and privacy concerns and safety issues associated with insulin pumps limit the growth of insulin pumps global market.
The insulin pumps global market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Major players in the insulin pumps market include Medtronic PLC (Ireland), Insulet Corporation (U.S.), Tandem Diabetes Care Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Ypsomed Holdings AG (Switzerland), Zealand Pharma (Valeritas) (Denmark), SOOIL development (South Korea), Debiotech S.A. (France), and Microtech Medical, Inc (China).
2 INTRODUCTION 25
2.1 KEY TAKEAWAYS 25
2.2 SCOPE OF THE REPORT 25
2.3 REPORT DESCRIPTION 26
2.4 MARKETS COVERED 28
2.5 STAKEHOLDERS 29
2.6 RESEARCH METHODOLOGY 29
2.6.1 MARKET SIZE ESTIMATION 31
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION 33
2.6.3 SECONDARY SOURCES 34
2.6.4 PRIMARY SOURCES 34
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES 35
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES 36
2.6.7 ASSUMPTIONS 36
3 MARKET ANALYSIS 40
3.1 INTRODUCTION 40
3.2 MARKET SEGMENTATION 41
3.3 FACTORS INFLUENCING MARKET 43
3.3.1 DRIVERS AND OPPORTUNITIES 44
3.3.1.1 The global rise in the prevalence and incidence of diabetes 44
3.3.1.2 Increase in the use of insulin pumps in-home care settings and disadvantages
of conventional methods over insulin pumps. 45
3.3.1.3 Increasing distribution agreements, partnerships and collaboration activities 46
3.3.1.4 Increase in product approvals 47
3.3.2 RESTRAINTS AND THREATS 47
3.3.2.1 High cost of the continuous subcutaneous insulin infusion therapy (CSII) 47
3.3.2.2 Inadequate reimbursement 48
3.3.2.3 Increased product recalls 49
3.3.2.4 Privacy concern and safety issues associated with insulin pumps 49
3.3.2.5 Stringent regulatory requirements for new products 50
3.4 REGULATORY AFFAIRS 52
3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION 52
3.4.1.1 ISO:9001: 2015 Quality Management System 52
3.4.1.2 ISO:13485 Medical Devices 52
3.4.2 U.S. 53
3.4.3 CANADA 55
3.4.4 EUROPE 56
3.4.5 INDIA 58
3.4.6 CHINA 59
3.4.7 JAPAN 60
3.5 FUNDING 61
3.6 DEALS 63
3.7 PORTER’S FIVE FORCE ANALYSIS 67
3.7.1 THREAT OF NEW ENTRANTS 68
3.7.2 THREAT OF SUBSTITUTES 69
3.7.3 RIVALRY AMONG EXISTING COMPETITORS 69
3.7.4 BARGAINING POWER OF SUPPLIERS 71
3.7.5 BARGAINING POWER OF BUYERS 71
3.8 CLINICAL TRIALS 72
3.9 SUPPLY CHAIN ANALYSIS 73
3.10 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 77
3.10.1 INSULIN PUMPS MARKET SHARE ANALYSIS 77
3.11 MARKET PENETRATION 80
3.11.1 GLOBAL TYPE 1 DIABETES INSULIN PUMP MARKET PENETRATION ANALYSIS 80
3.11.2 GLOBAL TYPE 2 DIABETES INSULIN PUMP MARKET PENETRATION ANALYSIS 82
3.11.3 N.A. TYPE 1 DIABETES INSULIN PUMP MARKET PENETRATION ANALYSIS 84
3.11.4 N.A. TYPE 2 DIABETES INSULIN PUMP MARKET PENETRATION ANALYSIS 85
3.11.5 E.U. TYPE 1 DIABETES INSULIN PUMP MARKET PENETRATION ANALYSIS 86
3.11.6 E.U. TYPE 2 DIABETES INSULIN PUMP MARKET PENETRATION ANALYSIS 87
3.11.7 APAC TYPE 1 DIABETES INSULIN PUMP MARKET PENETRATION ANALYSIS 88
3.11.8 APAC TYPE 2 DIABETES INSULIN PUMP MARKET PENETRATION ANALYSIS 89
3.11.9 ROW TYPE 1 DIABETES INSULIN PUMP MARKET PENETRATION ANALYSIS 90
3.11.10 ROW TYPE 2 DIABETES INSULIN PUMP MARKET PENETRATION ANALYSIS 91
4 INSULIN PUMPS GLOBAL MARKET, BY PRODUCTS 93
4.1 INTRODUCTION 93
4.2 INSULIN PUMP DEVICES 95
4.2.1 TETHERED INSULIN PUMP 100
4.2.2 PATCH INSULIN PUMP 103
4.3 CONSUMABLES 105
5 INSULIN PUMPS GLOBAL MARKET, BY APPLICATION 111
5.1 INTRODUCTION 111
5.2 TYPE 1 DIABETES 113
5.3 TYPE 2 DIABETES 116
6 INSULIN PUMPS GLOBAL MARKET, BY UTILITY 119
6.1 INTRODUCTION 119
6.2 DURABLE INSULIN PUMP 122
6.3 DISPOSABLE INSULIN PUMP 124
6.3.1 PARTIALLY DISPOSABLE INSULIN PUMP 128
6.3.2 FULLY DISPOSABLE INSULIN PUMP 129
7 INSULIN PUMPS GLOBAL MARKET, BY END-USER 131
7.1 INTRODUCTION 131
7.2 HOSPITALS 134
7.3 AMBULATORY SURGICAL CENTERS 136
7.4 HOME HEALTHCARE 137
7.5 OTHERS 140
8 INSULIN PUMPS GLOBAL MARKET, BY REGION 143
8.1 INTRODUCTION 143
8.2 NORTH AMERICA 146
8.2.1 U.S. 159
8.2.2 REST OF NORTH AMERICA 165
8.3 EUROPE 173
8.3.1 GERMANY 184
8.3.2 FRANCE 189
8.3.3 ITALY 194
8.3.4 REST OF EUROPE 199
8.4 APAC 205
8.4.1 JAPAN 217
8.4.2 CHINA 222
8.4.3 INDIA 227
8.4.4 REST OF APAC 232
8.5 REST OF THE WORLD 237
8.5.1 BRAZIL 250
8.5.2 TURKEY 255
8.5.3 OTHERS 260
9 COMPETITIVE LANDSCAPE 267
9.1 INTRODUCTION 267
9.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 268
9.3 NEW PRODUCT LAUNCH 271
9.4 APPROVAL 274
9.5 ACQUISITION 275
9.6 FUNDING 276
9.7 OTHERS 276
10 MAJOR COMPANIES 278
10.1 DEBIOTECH S.A. 278
10.1.1 OVERVIEW 278
10.1.2 FINANCIALS 279
10.1.3 PRODUCT PORTFOLIO 279
10.1.4 KEY DEVELOPMENTS 279
10.1.5 BUSINESS STRATEGY 279
10.1.6 SWOT ANALYSIS 280
10.2 INSULET CORPORATION 281
10.2.1 OVERVIEW 281
10.2.2 FINANCIALS 282
10.2.3 PRODUCT PORTFOLIO 284
10.2.4 KEY DEVELOPMENTS 285
10.2.5 BUSINESS STRATEGY 286
10.2.6 SWOT ANALYSIS 287
10.3 MEDTRONIC, PLC 288
10.3.1 OVERVIEW 288
10.3.2 FINANCIALS 289
10.3.3 PRODUCT PORTFOLIO 291
10.3.4 KEY DEVELOPMENTS 292
10.3.5 BUSINESS STRATEGY 293
10.3.6 SWOT ANALYSIS 294
10.4 MICROTECH MEDICAL, INC. 295
10.4.1 OVERVIEW 295
10.4.2 FINANCIALS 296
10.4.3 PRODUCT PORTFOLIO 296
10.4.4 KEY DEVELOPMENTS 296
10.4.5 BUSINESS STRATEGY 296
10.4.6 SWOT ANALYSIS 297
10.5 F. HOFFMANN-LA ROCHE AG. 298
10.5.1 OVERVIEW 298
10.5.2 FINANCIALS 299
10.5.3 PRODUCT PORTFOLIO 302
10.5.4 KEY DEVELOPMENTS 303
10.5.5 BUSINESS STRATEGY 304
10.5.6 SWOT ANALYSIS 305
10.6 SOOIL DEVELOPMENT CO. LTD. 306
10.6.1 OVERVIEW 306
10.6.2 FINANCIALS 306
10.6.3 PRODUCT PORTFOLIO 306
10.6.4 KEY DEVELOPMENTS 307
10.6.5 BUSINESS STRATEGY 307
10.6.6 SWOT ANALYSIS 308
10.7 TANDEM DIABETES CARE INC. 309
10.7.1 OVERVIEW 309
10.7.2 FINANCIALS 310
10.7.3 PRODUCT PORTFOLIO 312
10.7.4 KEY DEVELOPMENTS 312
10.7.5 BUSINESS STRATEGY 314
10.7.6 SWOT ANALYSIS 315
10.8 YPSOMED HOLDING AG. 316
10.8.1 OVERVIEW 316
10.8.2 FINANCIALS 317
10.8.3 PRODUCT PORTFOLIO 318
10.8.4 KEY DEVELOPMENTS 319
10.8.5 BUSINESS STRATEGY 320
10.8.6 SWOT ANALYSIS 321
10.9 ZEALAND PHARMA 322
10.9.1 OVERVIEW 322
10.9.2 FINANCIALS 323
10.9.3 PRODUCT PORTFOLIO 323
10.9.4 KEY DEVELOPMENTS 324
10.9.5 BUSINESS STRATEGY 324
10.9.6 SWOT ANALYSIS 325
10.10 ZHENGZHOU PHRAY TECHNOLOGY CO., LTD. 326
10.10.1 OVERVIEW 326
10.10.2 FINANCIALS 326
10.10.3 PRODUCT PORTFOLIO 326
10.10.4 KEY DEVELOPMENTS 326
10.10.5 BUSINESS STRATEGY 327
10.10.6 SWOT ANALYSIS 327
Related Report
